

| | | |
|--|-----------------------------------|--------------|
| SOP30103: Initial Culture, Sub-culture, and Cryopreservation of Adherent Patient-Derived Tumor Cultures (PDCs) | | |
| Laboratory: | Patient-Derived Models Repository | |
| Revision Date: | 9/1/2020 | Page 1 of 11 |

Table of Contents

| | |
|--|----|
| RELATED DOCUMENTS | 1 |
| 1.0 PURPOSE/SCOPE | 2 |
| 2.0 SAFETY | 2 |
| 3.0 CLEAN-UP..... | 2 |
| 4.0 EQUIPMENT | 3 |
| 5.0 GENERAL WORKFLOW | 4 |
| 6.0 RECOVERY FROM CRYO-PRESERVATION | 5 |
| 7.0 EXPANSION FOR ESTABLISHING A MASTER SEED STOCK | 6 |
| 8.0 SUB-CULTURE CONDITIONS..... | 7 |
| 9.0 CRYOPRESERVATION PROCEDURE..... | 8 |
| APPENDIX 1: ALTERNATE CULTURE CONDITIONS | 10 |
| APPENDIX 2: PHASE CONTRAST IMAGES OF PDCS | 11 |

Change History

| Revision | Description |
|------------|--|
| | Internal SOP used by PDMR In Vitro Laboratory |
| 10/15/2017 | Standardize SOP for posting to PDMR internal site for use by designated NCI intramural laboratories |
| 5/14/2018 | Added pictogram workflow from cell culture receipt to master cell stock (MCS) preparation. Updated reference SOPs and Purpose/Scope section. Added details on establishment of MCS. Added Appendix 1 providing guidance on changing cell culture conditions. |
| 6/28/2018 | Details on disassociation of PDX-derived cell cultures using Accutase added. Appendix 2 added with representative PDC Images. |
| 1/16/2019 | Updated split recommendations for making master cell stock (MCS) and Freeze Medium recipe |
| 9/1/2020 | Corrected error in Trypsin concentration from 0.25% to 0.05%; catalog number remains the same |

RELATED DOCUMENTS

Available on the PDMR website: <https://pdmr.cancer.gov/sops>

| |
|--|
| SOP30101: Recipes for Complete Media for Patient-Derived In Vitro and Organoid Cultures |
| SOP30102: Preparation of Matrigel-Coated Flasks for Adherent Patient-Derived In Vitro Cultures |

| | | |
|--|-----------------------------------|--------------|
| SOP30103: Initial Culture, Sub-culture, and Cryopreservation of Adherent Patient-Derived Tumor Cultures (PDCs) | | |
| Laboratory: | Patient-Derived Models Repository | |
| Revision Date: | 9/1/2020 | Page 2 of 11 |

1.0 PURPOSE/SCOPE

This Standing Operating Procedure (SOP) describes common tissue culture media used for growth of Adherent Patient-Derived Tumor Cultures (PDCs) under BSL-2 safety criteria. Early-passage patient-derived in vitro cultures require different growth conditions, have different growth characteristics, and visually appear different than traditional cell cultures (e.g., HeLa); see [Appendix 2](#). The recommended tissue culture media for **each specific** culture are provided as part of the Certificate of Analysis for the culture. **Not all cultures will use the same media.**

This SOP is used/performed by the Biological Testing Branch (BTB) at NCI-Frederick, Frederick National Laboratory for Cancer Research.

2.0 SAFETY

BTB treats all patient-derived in vitro cell cultures under Biosafety Level 2 (BSL2) conditions even when PCR-based screening has not detected the presence of a known set of human pathogens. All work is conducted in a biological safety cabinet (BSC) using personal protective equipment and avoiding the use of sharps where possible. All materials potentially exposed to the cell cultures are disinfected by exposure to a 10% bleach solution for a minimum of 10 minutes, double bagging for autoclaving or incineration. Consult with your facility safety professionals regarding the safe handling of BSL2 studies.

3.0 CLEAN-UP

- 3.1 All materials in contact with patient tissue as well as cultures derived from patient tumor samples are treated as a potential health threat (BSL-2 precautions) since the human tissues could retain human pathogenic agents even if they do not replicate in mouse cells (e.g., EBV, HPV, etc).
- 3.2 Flush/soak any items (e.g., tubes, syringes, petri dishes, lab mats, etc) that were in contact with human tissue with disinfectant (e.g., 10% bleach, commercial hydrogen peroxide disinfectant, 2% Virkon®) for a minimum of 10 minutes before disposal in biohazard waste or sharps containers (follow institutional guidelines and manufacturer's recommendations).
- 3.3 For items that can't be rinsed (e.g., micropipettors), wipe down thoroughly with bleach-soaked gauze or other appropriate disinfectants.

| | | |
|--|-----------------------------------|--------------|
| SOP30103: Initial Culture, Sub-culture, and Cryopreservation of Adherent Patient-Derived Tumor Cultures (PDCs) | | |
| Laboratory: | Patient-Derived Models Repository | |
| Revision Date: | 9/1/2020 | Page 3 of 11 |

4.0 EQUIPMENT


4.1 Reagents

- 4.1.1 Complete Media **without** Y-compound: sufficient volume for thawing steps
- 4.1.2 Complete Media (including Y-compound)
- 4.1.3 Matrigel-coated T25 flask (SOP30102)
- 4.1.4 DPBS (Invitrogen, Cat#: 14190250) or HBSS (Invitrogen, Cat#: 14175-079)
- 4.1.5 0.05% (w/v) Trypsin-EDTA (Invitrogen, Cat#: 25300120)
- 4.1.6 Accutase, in DPBS without Ca⁺⁺ or Mg⁺⁺ (Innovative Cell Technologies, Inc., Cat#: AT-104)
- 4.1.7 Fetal Bovine Serum (Hyclone, Cat#: SH30070.03 – HI)
- 4.1.8 DMSO, HPLC-grade, >99.5% pure (Honeywell Research Chemicals/Burdick & Jackson, Cat#: 081-1L)

4.2 Material & Equipment

- 4.2.1 50-mL, 25-mL, 10-mL, 5-mL pipettes, sterile
- 4.2.2 15 and 50-mL polypropylene tubes, sterile
- 4.2.3 2.0 mL screw-capped cryovials ((Nunc, Cat#: 368632)
- 4.2.4 Tissue Culture flasks, sterile, vented
- 4.2.5 Pipetman and sterile tips
- 4.2.6 Waste container Bleach (Clorox, 5.25% Hypochlorite) diluted 1:10, 2% Virkon®, or similar disinfectant
- 4.2.7 Refrigerator (4°C) and freezer (–20°C)
- 4.2.8 37°C Incubator (5% CO₂, humidified)
- 4.2.9 Biological Safety Cabinet (BSC) meeting biosafety level 2 (BSL2) standards
- 4.2.10 Personal Protective Equipment (PPE) at a minimum laboratory coat, with fitted sleeves, latex or nitrile gloves and safety glasses

5.0 GENERAL WORKFLOW



| | | |
|--|-----------------------------------|--------------|
| SOP30103: Initial Culture, Sub-culture, and Cryopreservation of Adherent Patient-Derived Tumor Cultures (PDCs) | | |
| Laboratory: | Patient-Derived Models Repository | |
| Revision Date: | 9/1/2020 | Page 5 of 11 |

6.0 RECOVERY FROM CRYO-PRESERVATION

- 6.1 In a sterile 15-mL conical tube, add 9-mL of the appropriate Complete Media (per the PDC-specific Certificate of Analysis [COA]) **without** Y-compound for the cells being thawed.
- 6.2 Quickly thaw the frozen cells by gently shaking the vial in a 37°C water bath. As soon as the cells start to thaw (should not be completely thawed), move to the BSC and clean the exterior of the tube with Virkon (or similar disinfectant).
- 6.3 Transfer the cells to the media-containing 15-mL conical tube.
- 6.4 Gently invert the tube several times to ensure the cells mix with the fresh Complete Media **without** Y-compound then centrifuge 200xg for 5 min.
- 6.5 Carefully pipette off the media, add 10-mL fresh Complete Media **without** Y-compound. Invert gently several times and repeat the centrifugation step.
- 6.6 Carefully pipette off the media and add 10-mL of fresh Complete Media **containing** 10 µM Y-compound. Gently resuspend the cells.
- 6.7 Carefully remove excess media from the Matrigel-coated T25 flask and discard taking care to not dislodge the Matrigel[®] coating.
- 6.8 Gently add the resuspended cells to the Matrigel[®]-coated T25 flask being careful to not dislodge the Matrigel[®] coating.
- 6.9 Incubate flask at 37°C in a 5% CO₂ humidified incubator.

| | | |
|--|-----------------------------------|--------------|
| SOP30103: Initial Culture, Sub-culture, and Cryopreservation of Adherent Patient-Derived Tumor Cultures (PDCs) | | |
| Laboratory: | Patient-Derived Models Repository | |
| Revision Date: | 9/1/2020 | Page 6 of 11 |

7.0 EXPANSION FOR ESTABLISHING A MASTER SEED STOCK

- Splitting:
 - Split cultures at approximately 70%-80% confluence. Do not allow cells to reach 100% confluence.

7.1 Enzymatic Disassociation Method is Origin Dependent

7.1.1 For Patient-Derived and PDX-Derived PDC cultures, when SOP states “Use appropriate enzymatic protocol” do the following steps:

7.1.1.1 Add 2-3 mL 0.05% (w/v) trypsin to the T25 flask and return flask to 37°C incubator for 3-5 min. Gently tap/rock flask to dislodge cells

7.1.1.2 Add at least twice the volume of Complete Media to the flask and mix with gentle pipetting. Transfer media/cell mixture to a sterile 50-mL conical tube.

7.1.2 For Organoid-Derived PDC cultures, when SOP states “Use appropriate enzymatic protocol” do the following steps:

7.1.2.1 Add 2-3 mL Accutase to the T25 flask and return flask to 37°C incubator for 20-30 min, checking the cells every 10 min. Gently tap/rock flask to dislodge cells.

7.1.2.2 Add at least twice the volume of Complete Media to the flask and mix with gentle pipetting. Transfer media/cell mixture to a sterile 50-mL conical tube.

- **Important:** Use of trypsin to disassociate Organoid-derived PDC cultures may result in substantial cell death.

7.2 To ensure successful expansion and banking of cells for future use, expand as follows and continue to use the recommended Complete Media (per the PDC-specific COA).

7.3 Split the initial T25 flask 1:2 as follows:

7.3.1 Aspirate and discard the media into an appropriate waste container.

7.3.2 Gently, rinse cells with 3-mL sterile DPBS or HBSS.

7.3.3 **Use appropriate enzymatic protocol** in SOP Step 7.1 to disassociate the cells.

7.3.4 Centrifuge for 5-6 min at 200xg and then discard culture media in appropriate waste container.

7.3.5 Resuspend cell pellet in 20-mL Complete Media. Triturate gently to completely resuspend cells.

7.3.6 Add 10 mL of the Complete Media/cell mixture into two new Matrigel-coated T25 flasks.

7.3.7 Place flasks in a humidified 5% CO₂ 37°C incubator.

7.4 Monitor cells microscopically at least twice each week.

| | | |
|--|-----------------------------------|--------------|
| SOP30103: Initial Culture, Sub-culture, and Cryopreservation of Adherent Patient-Derived Tumor Cultures (PDCs) | | |
| Laboratory: | Patient-Derived Models Repository | |
| Revision Date: | 9/1/2020 | Page 7 of 11 |

- 7.5** Repeat splitting culture using the recommended split ratio in the PDC-specific COA until a total of 16 flasks of cells have been established.
- 7.6** Once the 16 flasks are ready to be split, 14 flasks should be used to establish a Master Cell Stock (MCS). The MCS will be used for re-establishment of culture material for experimental work.
- 7.6.1** Follow procedures for cryopreservation in SOP Step 9.0.
- 7.6.2** MCS material should be authenticated by Short Tandem Repeat (STR) analysis and compared to the PDMR reported STR profile, undergo microbial/sterility testing, and should be tested to verify cell count and viability.
- 7.7** The remaining two (2) T25 flasks should be split using the recommended split ratio in the PDC-specific COA to pursue experimental questions.

Note: Seed Stocks and Working Stocks can be established using the same methodology to increase the amount of banked material ready for experimental use.

8.0 SUB-CULTURE CONDITIONS

8.1 General Notes

- Splitting:
 - Split cultures at approximately 70%-80% confluence. **Do not** allow cells to reach 100% confluence.
 - The recommended split ratio for actively growing cultures is included in the PDC-specific COA provided with the cell line. Primary cell cultures are sensitive to cell density; follow the provided recommendations.
- Change media every 7 days. Change more frequently if the media turns yellow
- Y-compound is included in most Complete Media recipes. See [Appendix 1](#) for recommendations on testing removal of Y-compound, moving to uncoated flasks, or trying different media conditions.

8.2 Sub-culture Method

- 8.2.1** Aspirate and discard the media into an appropriate waste container.
- 8.2.2** Gently, rinse cells with 3-mL sterile DPBS or HBSS.
- 8.2.3** **Use appropriate enzymatic protocol** in SOP Step 7.1 to disassociate the cells.
- 8.2.4** Centrifuge cells for 5-6 min at 200xg.
- 8.2.5** Discard culture media in appropriate waste container.
- 8.2.6** Resuspend cell pellet in the appropriate volume of Complete Media (per COA) to accommodate recommended split ratio (per COA).
- 8.2.7** Add cells to flasks and place flasks in a humidified 5% CO₂ 37°C incubator.
- 8.2.8** Monitor cells microscopically at least twice each week.

| | | |
|--|-----------------------------------|--------------|
| SOP30103: Initial Culture, Sub-culture, and Cryopreservation of Adherent Patient-Derived Tumor Cultures (PDCs) | | |
| Laboratory: | Patient-Derived Models Repository | |
| Revision Date: | 9/1/2020 | Page 8 of 11 |

9.0 CRYOPRESERVATION PROCEDURE

9.1 Prepare Freeze Media

| Item | Final Percent/Volume |
|---|----------------------|
| Complete Media (per COA); which already contains 5% FBS | 80% |
| Fetal Bovine Serum* | 15% |
| DMSO | 10% |

*Note Fetal Bovine Serum final concentration will be approximately 20% from Complete Media + additional FBS added in Freeze Media Recipe.

9.2 Cryopreservation

- 9.2.1 Aspirate and discard culture medium from flask into an appropriate waste container.
- 9.2.2 Rinse cells in flask with 3 mL sterile DPBS or HBSS.
- 9.2.3 **Use appropriate enzymatic protocol** in SOP Step 7.1 to disassociate the cells.
- 9.2.4 Centrifuge cells for 5-6 min at 200xg.
- 9.2.5 Discard culture media in appropriate waste container.
- 9.2.6 Resuspend cell pellet in a small volume of Freeze Media. For example, for MCS establishment from 14 flasks of cells, resuspend in 3 mL.
 - 9.2.6.1 Remove a small aliquot of cells for cell counting (e.g., 25 μ L).
 - 9.2.6.2 Count viable cells by trypan blue exclusion, or similar.
- 9.2.7 Add additional Freeze Media to the cell/Freeze Media suspension to reach a target of 1×10^6 viable cells/mL in Freeze Media.
- 9.2.8 Aliquot 1-mL of cell suspension into 2.0 mL screw-capped cryovials. Apply the cap to the cryovials, seal well.
- 9.2.9 Wipe the exterior with disinfectant then place into wet ice until ready to begin stepped-rate freezing (cooling rate of $-1^\circ\text{C}/\text{minute}$).

| | | |
|--|-----------------------------------|--------------|
| SOP30103: Initial Culture, Sub-culture, and Cryopreservation of Adherent Patient-Derived Tumor Cultures (PDCs) | | |
| Laboratory: | Patient-Derived Models Repository | |
| Revision Date: | 9/1/2020 | Page 9 of 11 |

9.3 Stepped -Rate Cryopreservation Procedure

9.3.1 Mechanically controlled stepped-rate freeze cryopreservation is recommended, when available, as it is believed to result in a lower loss of cell viability due to the decreased formation of ice crystals.

9.3.2 Always follow the manufacturer's guidelines for operation. General stepped-rate cryopreservation parameters used at by the PDMR are:

- Decrease 1°C/minute down to -4°C
- Decrease 25°C/minute down to -40°C
- Increase 15°C/minute up to -12°C
- Decrease 1°C/minute down to -40°C
- Decrease 10°C/minute down to -90°C

9.3.3 Vials should be transferred to the vapor phase of a liquid nitrogen tank as soon as practical after the vials reach minimum temperature. Preferably within 4-6 hours. In no case, should the vials be held longer than 24-hours before transfer into the vapor phase of a liquid nitrogen storage tank.

9.4 Slow-rate freezing (isopropanol-based using a cryo -1°C cell-freezing container such as Mr. Frosty Freeze Container [Sigma-Aldrich, Cat#: C1562])

9.4.1 Follow the manufacturer's instructions as provided for the specific cryopreservation device.

9.4.2 Material should be held on wet ice in cryovial tubes until ready for placement into the slow-rate freeze container.

9.4.3 The base of the cryo-container is filled with isopropanol per the manufacturer's recommendation and the tube holder is placed on top.

9.4.4 Transfer the cryovials filled with cells/freeze media from the ice-bucket into the tube holder of the cryo-container, screw the lid securely onto the cryo-container, and place at -80°C for a minimum of 4 hours, but most commonly for overnight.


9.4.5 Vials should be transferred to the vapor phase of a liquid nitrogen tank as soon as practical after the 4-hour freeze step. Preferably within 4-6 hours. In no case, should the vials be held longer than 24-hours before transfer into the vapor phase of a liquid nitrogen storage tank.

9.5 Slow-rate freezing (non-isopropanol based such as CoolCell)

9.5.1 Follow the manufacturer's instructions as provided for the specific cryopreservation device.

APPENDIX 1: ALTERNATE CULTURE CONDITIONS

- Changes to culture conditions should not be attempted until the Master Cell Stock (MCS) has been banked. If the MCS needs to be regenerated, the recommended Complete Media for the culture as outlined in the PDC-specific COA should be used.
- Changes to culture conditions should only be attempted on well-established cultures with MCS available for recovery, at least 3-4 passages after thawing.
- Changing culture conditions may result in changes to the cell culture composition, SNP allele frequency, RNA and protein expression levels, etc. Any publications should note all changes to culture conditions relative to the provided PDMR material.
- To minimize shock to the patient-derived cells, changes should be performed in a step-wise controlled manner. Below is a recommended workflow for changing culture conditions. Always maintain one flask in the previous culture conditions in case the change results in cell death.



APPENDIX 2: PHASE CONTRAST IMAGES OF PDCS

Representative images (40x) of PDC cultures from multiple histologies to demonstrate the range of phenotypes that can be expected in adherent and suspension/suspension cluster (yellow boxes) growth types.

